281 related articles for article (PubMed ID: 34112084)
1. Associated risk factors with disease severity and antiviral drug therapy in patients with COVID-19.
Gong X; Kang S; Guo X; Li Y; Gao H; Yuan Y
BMC Infect Dis; 2021 Jun; 21(1):549. PubMed ID: 34112084
[TBL] [Abstract][Full Text] [Related]
2. Clinical predictive risk factors prolonged the duration of SARS-CoV-2 clearance in 279 moderate COVID-19 patients: A multicenter retrospective cohort study.
Wu X; Zhou S; Liu C; Huang T; Zheng Y; Zhang W; Qu Y; Fang B
Medicine (Baltimore); 2021 Oct; 100(40):e27410. PubMed ID: 34622847
[TBL] [Abstract][Full Text] [Related]
3. Prolonged SARS-CoV-2 Viral Shedding in Patients with COVID-19 was Associated with Delayed Initiation of Arbidol Treatment and Consulting Doctor Later: A Retrospective Cohort Study.
He XL; Zhou YY; Fu W; Xue YE; Liang MY; Yang BH; Ma WL; Zhou Q; Chen L; Zhang JC; Wang XR
Curr Med Sci; 2021 Dec; 41(6):1096-1104. PubMed ID: 34515914
[TBL] [Abstract][Full Text] [Related]
4. Effect of early oxygen therapy and antiviral treatment on disease progression in patients with COVID-19: A retrospective study of medical charts in China.
Long L; Wu L; Chen L; Zhou D; Wu H; Lu D; Li H; Duan X; Han Y; Li X; Wang Q; Zhang J
PLoS Negl Trop Dis; 2021 Jan; 15(1):e0009051. PubMed ID: 33406076
[TBL] [Abstract][Full Text] [Related]
5. Identification of risk factors for in-hospital death of COVID - 19 pneumonia -- lessions from the early outbreak.
Wang Z; Wang Z
BMC Infect Dis; 2021 Jan; 21(1):113. PubMed ID: 33494706
[TBL] [Abstract][Full Text] [Related]
6. Factors Associated with a Positive Severe Acute Respiratory Syndrome Coronavirus 2 Testing in Suspected Cases Presenting with Pneumonia: A Retrospective Cohort Study in a Single Medical Center.
Li Y; Shang Y; Yang Y; Wang M; Yu D; Su D; Liu L; Wang Q; Zhang X; Ren J; Chen H
Respiration; 2020; 99(9):739-747. PubMed ID: 33207356
[TBL] [Abstract][Full Text] [Related]
7. Antiviral drugs arbidol and interferon alpha-1b contribute to reducing the severity of COVID-19 patients: a retrospective cohort study.
Yin P; Meng J; Chen J; Gao J; Wang D; Liu S; Guo Q; Zhu M; Zhang G; Liu Y; Li Y; Zhang G
Virol J; 2021 Jul; 18(1):142. PubMed ID: 34238341
[TBL] [Abstract][Full Text] [Related]
8. Arbidol is associated with increased in-hospital mortality among 109 patients with severe COVID-19: A multicenter, retrospective study.
Zhou X; Hou H; Yang L; Ding G; Wei T; Li C; Heng Y; Liu R; Ma M; Hu Z; Huang L; Xu X; Hu Q; Zhao Y; Xing W; Zhao Z
J Glob Health; 2021; 11():05017. PubMed ID: 34326998
[TBL] [Abstract][Full Text] [Related]
9. Clinical features of patients with coronavirus disease 2019 from a designated hospital in Beijing, China.
Sun L; Shen L; Fan J; Gu F; Hu M; An Y; Zhou Q; Fan H; Bi J
J Med Virol; 2020 Oct; 92(10):2055-2066. PubMed ID: 32369208
[TBL] [Abstract][Full Text] [Related]
10. Possibility of deterioration of respiratory status when steroids precede antiviral drugs in patients with COVID-19 pneumonia: A retrospective study.
Shionoya Y; Taniguchi T; Kasai H; Sakuma N; Imai S; Shikano K; Takayanagi S; Yahaba M; Nakada TA; Igari H; Sakao S; Suzuki T
PLoS One; 2021; 16(9):e0256977. PubMed ID: 34473766
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.
Tian J; Yuan X; Xiao J; Zhong Q; Yang C; Liu B; Cai Y; Lu Z; Wang J; Wang Y; Liu S; Cheng B; Wang J; Zhang M; Wang L; Niu S; Yao Z; Deng X; Zhou F; Wei W; Li Q; Chen X; Chen W; Yang Q; Wu S; Fan J; Shu B; Hu Z; Wang S; Yang XP; Liu W; Miao X; Wang Z
Lancet Oncol; 2020 Jul; 21(7):893-903. PubMed ID: 32479790
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics and risk factors for severity of COVID-19 outside Wuhan: a double-center retrospective cohort study of 213 cases in Hunan, China.
Hu X; Hu C; Yang Y; Chen J; Zhong P; Wen Y; Chen X
Ther Adv Respir Dis; 2020; 14():1753466620963035. PubMed ID: 33138694
[TBL] [Abstract][Full Text] [Related]
13. Symptoms and Health Outcomes Among Survivors of COVID-19 Infection 1 Year After Discharge From Hospitals in Wuhan, China.
Zhang X; Wang F; Shen Y; Zhang X; Cen Y; Wang B; Zhao S; Zhou Y; Hu B; Wang M; Liu Y; Miao H; Jones P; Ma X; He Y; Cao G; Cheng L; Li L
JAMA Netw Open; 2021 Sep; 4(9):e2127403. PubMed ID: 34586367
[TBL] [Abstract][Full Text] [Related]
14. Clinical features and efficacy of antiviral drug, Arbidol in 220 nonemergency COVID-19 patients from East-West-Lake Shelter Hospital in Wuhan: a retrospective case series.
Gao W; Chen S; Wang K; Chen R; Guo Q; Lu J; Wu X; He Y; Yan Q; Wang S; Wang F; Jin L; Hua J; Li Q
Virol J; 2020 Oct; 17(1):162. PubMed ID: 33097047
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
[TBL] [Abstract][Full Text] [Related]
16. Beneficial effect of Arbidol in the management of COVID-19 infection.
Jie X; Hongmei Y; Ping F; Kuikui Z; Bohan Y; Rui M
Aging (Albany NY); 2021 Apr; 13(7):9253-9264. PubMed ID: 33811756
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study.
Bartoletti M; Marconi L; Scudeller L; Pancaldi L; Tedeschi S; Giannella M; Rinaldi M; Bussini L; Valentini I; Ferravante AF; Potalivo A; Marchionni E; Fornaro G; Pascale R; Pasquini Z; Puoti M; Merli M; Barchiesi F; Volpato F; Rubin A; Saracino A; Tonetti T; Gaibani P; Ranieri VM; Viale P; Cristini F;
Clin Microbiol Infect; 2021 Jan; 27(1):105-111. PubMed ID: 32971254
[TBL] [Abstract][Full Text] [Related]
18. Comparison of acute pneumonia caused by SARS-COV-2 and other respiratory viruses in children: a retrospective multi-center cohort study during COVID-19 outbreak.
Ren GL; Wang XF; Xu J; Li J; Meng Q; Xie GQ; Huang B; Zhu WC; Lin J; Tang CH; Ye S; Li Z; Zhu J; Tang Z; Ma MX; Xie C; Wu YW; Liu CX; Yang F; Zhou YZ; Zheng Y; Lan SL; Chen JF; Ye F; He Y; Wu BQ; Chen L; Fu SM; Zheng CZ; Shi Y
Mil Med Res; 2021 Feb; 8(1):13. PubMed ID: 33593415
[TBL] [Abstract][Full Text] [Related]
19. Symptomatic features and prognosis of 932 hospitalized patients with coronavirus disease 2019 in Wuhan.
Sun LL; Wang J; Wang YS; Hu PF; Zhao ZQ; Chen W; Ning BF; Yin C; Hao YS; Wang Q; Wang C; Liu YL; Chen C; Yin JZ; Huang H; Xie WF
J Dig Dis; 2021 May; 22(5):271-281. PubMed ID: 33742780
[TBL] [Abstract][Full Text] [Related]
20. A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage: a structured summary of a study protocol for a randomized controlled trial.
Takayama S; Namiki T; Ito T; Arita R; Nakae H; Kobayashi S; Yoshino T; Ishigami T; Tanaka K; Kainuma M; Nochioka K; Takagi A; Mimura M; Yamaguchi T; Ishii T
Trials; 2020 Oct; 21(1):827. PubMed ID: 33008479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
